Download File - JOHN J. HADDAD, Ph.D.

Diagnostic Approaches to Maximize Therapeutic Effect 201
22. Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes.
Annu Rev Immunol 1989; 7:601–624.
23. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human
cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999; 5(4):
178–186.
24. Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from
T-cell recognition: molecular mechanisms and functional significance. Adv Immunol
2000; 74:181–273.
25. Leong AS. Pitfalls in diagnostic immunohistology. Adv Anat Pathol 2004; 11(2):
86–93.
26. Itoh Y, Mizuki N, Shimada T, et al. High-throughput DNA typing of HLA-A, -B, -C,
and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population.
Immunogenetics 2005; 57(10):717–729.
27. Crowley NJ, Darrow TL, Quinn-Allen MA, et al. MHC-restricted recognition of
autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction
by a dominant HLA-A allele. J Immunol 1991; 146(5):1692–1699.
28. Kawakami Y, Zakut R, Topalian SL, et al. Shared human melanoma antigens.
Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
J Immunol 1992; 148(2):638–643.
29. Anichini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes
share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma
patients. J Exp Med 1993; 177(4):989–998.
30. Natali PG, Nicotra MR, Bigotti A, et al. Selective changes in expression of HLA
class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci U S A
1989; 86(17):6719–6723.
31. Kageshita T, Wang Z, Calorini L, et al. Selective loss of human leukocyte class I
allospecificities and staining of melanoma cells by monoclonal antibodies recognizing
monomorphic determinants of class I human leukocyte antigens. Cancer Res
1993; 53(14):3349–3354.
32. Marincola FM, Ettinghausen S, Cohen PA, et al. Treatment of established lung
metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic
tumor engineered to secrete human TNF-alpha. J Immunol 1994; 152(7):3500–3513.
33. Li Y, Moysey R, Molloy PE, et al. Directed evolution of human T-cell receptors with
picomolar affinities by phage display. Nat Biotechnol 2005; 23(3):349–354.
34. Cohen CJ, Sarig O, Yamano Y, et al. Direct phenotypic analysis of human MHC
class I antigen presentation: visualization, quantitation, and in situ detection of
human viral epitopes using peptide-specific, MHC-restricted human recombinant
antibodies. J Immunol 2003; 170(8):4349–4361.
35. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite
the induction of very high levels of self/tumor antigen-specific CD8þ T cells in
patients with melanoma. J Immunol 2005; 175(9):6169–6176.
36. Speiser DE, Romero P, et al. Toward improved immunocompetence of adoptively
transferred CD8þ T cells. J Clin Invest 2005; 115(6):1467–1469.
37. Ayyoub M, Zippelius A, Pittet MJ, et al. Activation of human melanoma reactive
CD8þ T cells by vaccination with an immunogenic peptide analog derived from
Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res 2003; 9(2):
669–677.